Cargando…

Apolipoprotein B/Apolipoprotein A-I Ratio Is a Better Predictor of Cancer Mortality Compared with C-Reactive Protein: Results from Two Multi-Ethnic US Populations

Background: There is a lack of evidence regarding the link between apolipoproteins and cancer mortality. By using two nationally representative samples of US adults, we prospectively evaluated the associations between apolipoprotein B (apoB) levels and apoB/apoA-I ratio with cancer mortality. We als...

Descripción completa

Detalles Bibliográficos
Autores principales: Mazidi, Mohsen, Katsiki, Niki, Mikhailidis, Dimitri P., Radenkovic, Dina, Pella, Daniel, Banach, Maciej
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7019626/
https://www.ncbi.nlm.nih.gov/pubmed/31936330
http://dx.doi.org/10.3390/jcm9010170
_version_ 1783497563179057152
author Mazidi, Mohsen
Katsiki, Niki
Mikhailidis, Dimitri P.
Radenkovic, Dina
Pella, Daniel
Banach, Maciej
author_facet Mazidi, Mohsen
Katsiki, Niki
Mikhailidis, Dimitri P.
Radenkovic, Dina
Pella, Daniel
Banach, Maciej
author_sort Mazidi, Mohsen
collection PubMed
description Background: There is a lack of evidence regarding the link between apolipoproteins and cancer mortality. By using two nationally representative samples of US adults, we prospectively evaluated the associations between apolipoprotein B (apoB) levels and apoB/apoA-I ratio with cancer mortality. We also examined the role of C-reactive protein (CRP) in these associations. Materials and Methods: Adults aged ≥20 years, enrolled in the 3rd National Health and Nutrition Examination Survey (NHANES III, 1988–1994) and continuous NHANES (2005–2010), and followed up to 31 December 2011, were included in the analysis. Multiple Cox regressions were applied to evaluate the associations between the variables of interest and cancer mortality. Results: Overall, 7695 participants were included (mean age: 49.2 years; 50.4% men, median follow-up: 19.1 years). In the fully adjusted model, participants in the highest quartile (Q4) of apoB/apoA-I had a significantly greater risk for cancer mortality (hazard ratio (HR): 1.40; 95% confidence interval (CI): 1.25–1.93) compared with those in the first quartile (Q1). In the same model, a positive and significant association between apoB levels and cancer mortality was observed for individuals in Q3 (HR: 1.12; 95% CI: 1.09–1.16) and Q4 (HR: 1.17; 95% CI: 1.09–1.25) compared with those in Q1. When CRP levels were added in the analysis, the apoB/apoA-I ratio, but not apoB levels, remained significantly related to cancer mortality (Q4 = HR: 1.17; 95% CI: 1.09–1.25). In contrast, CRP levels were not able to predict cancer death after correction for apoB/apoA-I ratio. Conclusions: In a large representative sample of the US adult population, the apoB/apoA-I ratio and apoB levels significantly predicted cancer mortality, independently of several cardiometabolic risk factors. The predictive value of apoB/apoA-I, but not apoB levels, remained significant after taking into account CRP, whereas CRP was not associated with cancer mortality after adjustment for apoB/apoA-I ratio. If further evidence supports our findings, apoA-I and apoB measurements could be considered in general healthcare policies.
format Online
Article
Text
id pubmed-7019626
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-70196262020-03-09 Apolipoprotein B/Apolipoprotein A-I Ratio Is a Better Predictor of Cancer Mortality Compared with C-Reactive Protein: Results from Two Multi-Ethnic US Populations Mazidi, Mohsen Katsiki, Niki Mikhailidis, Dimitri P. Radenkovic, Dina Pella, Daniel Banach, Maciej J Clin Med Article Background: There is a lack of evidence regarding the link between apolipoproteins and cancer mortality. By using two nationally representative samples of US adults, we prospectively evaluated the associations between apolipoprotein B (apoB) levels and apoB/apoA-I ratio with cancer mortality. We also examined the role of C-reactive protein (CRP) in these associations. Materials and Methods: Adults aged ≥20 years, enrolled in the 3rd National Health and Nutrition Examination Survey (NHANES III, 1988–1994) and continuous NHANES (2005–2010), and followed up to 31 December 2011, were included in the analysis. Multiple Cox regressions were applied to evaluate the associations between the variables of interest and cancer mortality. Results: Overall, 7695 participants were included (mean age: 49.2 years; 50.4% men, median follow-up: 19.1 years). In the fully adjusted model, participants in the highest quartile (Q4) of apoB/apoA-I had a significantly greater risk for cancer mortality (hazard ratio (HR): 1.40; 95% confidence interval (CI): 1.25–1.93) compared with those in the first quartile (Q1). In the same model, a positive and significant association between apoB levels and cancer mortality was observed for individuals in Q3 (HR: 1.12; 95% CI: 1.09–1.16) and Q4 (HR: 1.17; 95% CI: 1.09–1.25) compared with those in Q1. When CRP levels were added in the analysis, the apoB/apoA-I ratio, but not apoB levels, remained significantly related to cancer mortality (Q4 = HR: 1.17; 95% CI: 1.09–1.25). In contrast, CRP levels were not able to predict cancer death after correction for apoB/apoA-I ratio. Conclusions: In a large representative sample of the US adult population, the apoB/apoA-I ratio and apoB levels significantly predicted cancer mortality, independently of several cardiometabolic risk factors. The predictive value of apoB/apoA-I, but not apoB levels, remained significant after taking into account CRP, whereas CRP was not associated with cancer mortality after adjustment for apoB/apoA-I ratio. If further evidence supports our findings, apoA-I and apoB measurements could be considered in general healthcare policies. MDPI 2020-01-08 /pmc/articles/PMC7019626/ /pubmed/31936330 http://dx.doi.org/10.3390/jcm9010170 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Mazidi, Mohsen
Katsiki, Niki
Mikhailidis, Dimitri P.
Radenkovic, Dina
Pella, Daniel
Banach, Maciej
Apolipoprotein B/Apolipoprotein A-I Ratio Is a Better Predictor of Cancer Mortality Compared with C-Reactive Protein: Results from Two Multi-Ethnic US Populations
title Apolipoprotein B/Apolipoprotein A-I Ratio Is a Better Predictor of Cancer Mortality Compared with C-Reactive Protein: Results from Two Multi-Ethnic US Populations
title_full Apolipoprotein B/Apolipoprotein A-I Ratio Is a Better Predictor of Cancer Mortality Compared with C-Reactive Protein: Results from Two Multi-Ethnic US Populations
title_fullStr Apolipoprotein B/Apolipoprotein A-I Ratio Is a Better Predictor of Cancer Mortality Compared with C-Reactive Protein: Results from Two Multi-Ethnic US Populations
title_full_unstemmed Apolipoprotein B/Apolipoprotein A-I Ratio Is a Better Predictor of Cancer Mortality Compared with C-Reactive Protein: Results from Two Multi-Ethnic US Populations
title_short Apolipoprotein B/Apolipoprotein A-I Ratio Is a Better Predictor of Cancer Mortality Compared with C-Reactive Protein: Results from Two Multi-Ethnic US Populations
title_sort apolipoprotein b/apolipoprotein a-i ratio is a better predictor of cancer mortality compared with c-reactive protein: results from two multi-ethnic us populations
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7019626/
https://www.ncbi.nlm.nih.gov/pubmed/31936330
http://dx.doi.org/10.3390/jcm9010170
work_keys_str_mv AT mazidimohsen apolipoproteinbapolipoproteinairatioisabetterpredictorofcancermortalitycomparedwithcreactiveproteinresultsfromtwomultiethnicuspopulations
AT katsikiniki apolipoproteinbapolipoproteinairatioisabetterpredictorofcancermortalitycomparedwithcreactiveproteinresultsfromtwomultiethnicuspopulations
AT mikhailidisdimitrip apolipoproteinbapolipoproteinairatioisabetterpredictorofcancermortalitycomparedwithcreactiveproteinresultsfromtwomultiethnicuspopulations
AT radenkovicdina apolipoproteinbapolipoproteinairatioisabetterpredictorofcancermortalitycomparedwithcreactiveproteinresultsfromtwomultiethnicuspopulations
AT pelladaniel apolipoproteinbapolipoproteinairatioisabetterpredictorofcancermortalitycomparedwithcreactiveproteinresultsfromtwomultiethnicuspopulations
AT banachmaciej apolipoproteinbapolipoproteinairatioisabetterpredictorofcancermortalitycomparedwithcreactiveproteinresultsfromtwomultiethnicuspopulations